RNTX vs RVPH

Rein Therapeutics, Inc. vs Reviva Pharmaceuticals Holdings — Valuation Comparison 2026

RNTX

Biotechnology
Rein Therapeutics, Inc.
Quality
3.6
out of 10
Value Trap
37
LOW
Price
$1.11
Last close
Models
7/13
Active
VS

RVPH

Biotechnology
Reviva Pharmaceuticals Holdings
Quality
3.7
out of 10
Value Trap
24
SAFE
Price
$0.43
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType RNTX Fair ValueRNTX Upside RVPH Fair ValueRVPH Upside
Bayesian DCF Intrinsic $0.03 -97.2% $1.03 +142.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.77 -30.6% $0.03 -96.6%
Dynamic NAV Asset-Based $0.32 -69.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNTX vs RVPH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNTX vs RVPH — Which Stock Is More Undervalued?

RVPH scores higher with a 3.7/10 quality rating vs RNTX's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rein Therapeutics, Inc. (RNTX) and Reviva Pharmaceuticals Holdings (RVPH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNTX currently trades at $1.11 with a QOC of 3.6/10, while RVPH trades at $0.43 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).